This is a working overview of forced degradation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
=== Cancer diagnosis === Although pathologic examination is the current standard method for molecular characterization in testing for the presence of biomarkers in tumors, these single-sample analyses fail to account for the diverse genomic nature of tumors. Considering the invasive nature, psychological stress, and the financial burden resulting from repeated tumor biopsies in patients, biomarkers that could be judged through minimally invasive procedures, such as blood draws, constitute an opportunity for progression in precision medicine. Liquid biopsy is an option that is becoming increasingly popular as an alternative to solid tumor biopsy. This is simply a blood draw that contains circulating tumor cells (CTCs) which are shed into the bloodstream from solid tumors. Patients with metastatic cancer are more likely to have detectable CTCs in the bloodstream but CTCs also exist in patients with localized diseases. It has been found that the number of CTCs present in the bloodstream of patients with metastatic prostate and colorectal cancer is prognostic of the overall survival of tumors. CTCs also have been demonstrated to inform prognosis in earlier stages of the disease.
== See also == Selenocysteine, another selenium-containing amino acid, but one that is incorporated into specific locations of specific proteins as directed by the genetic code. Selenoprotein Canadian Reference Material of selenomethionine
By 2014, around 20 companies, particularly from emerging markets, were developing biosimilar versions of trastuzumab after Roche/Genentech's patents expired in 2014 in Europe, and in 2019 in the United States. In January 2015, BIOCAD announced the first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation. Iran also approved its own version of the monoclonal antibody in January 2016, as AryoTrust, and announced its readiness to export the drug to other countries in the Middle-East and Central Asia when trade sanctions were lifted. In 2016, the investigational biosimilar MYL-1401O showed comparable efficacy and safety to the Herceptin branded trastuzumab. Trastuzumab-dkst (Ogivri, Mylan GmbH) was approved in the United States in December 2017, to "treat people with breast cancer or gastric or gastroesophageal junction adenocarcinoma whose tumors overexpress the HER-2 gene." Ogivri was authorized for medical use in the European Union in December 2018. In November 2017, the European Commission authorized Ontruzant, a biosimilar from Samsung Bioepis Co., Ltd, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. Ontruzant is the first trastuzumab biosimilar to receive regulatory approval in the European Union. Herzuma was authorized for medical use in the European Union in February 2018. Herzuma, a trastuzumab biosimilar, was approved in the United States in December 2018.
Veterinary pharmacies, sometimes called animal pharmacies, may fall in the category of hospital pharmacy, retail pharmacy or mail-order pharmacy. Veterinary pharmacies stock different varieties and different strengths of medications to fulfill the pharmaceutical needs of animals. Because the needs of animals, as well as the regulations on veterinary medicine, are often very different from those related to people, in some jurisdictions veterinary pharmacy may be kept separate from regular pharmacies.
To facilitate the work of the CDC, a Medical Laboratory Services Advisory Committee was appointed. Inhorn was the only State Laboratory Director to serve on the MLSAC Advisory Committee, perhaps because the WSLH had a strong history of proficiency testing in clinical laboratories in Wisconsin. Inhorn's assignment for CLIA-67 was to develop a protocol for PT programs to be used in the future. Many changes had been made to CLIA-67, but major weaknesses in the program still existed. It would take another two decades before new federal legislation, called CLIA-88, would address these shortcomings. Inhorn was appointed to the new CLIA-88 advisory board and served during the first two years of its existence. During the ensuing years, many more health laboratories opened in the U.S. and new technology introduced built-in controls, so that performance was validated without confirmation by laboratory workers.
Sources: en.wikipedia.org
=== Non-homologous isofunctional enzymes === Unrelated enzymes that have the same enzymatic activity have been called non-homologous isofunctional enzymes. Horizontal gene transfer may spread these genes to unrelated species, especially bacteria where they can replace endogenous genes of the same function, leading to hon-homologous gene displacement.
== Pathophysiology == Peyronie's disease develops in two phases: the acute (inflammatory) and chronic (fibrotic) phase. During the acute phase, microtrauma induces damage to the endothelium, fibrin deposition, and immigration of immune cells into the tunica albuginea. Fibroblast proliferation and myofibroblast differentiation are promoted by cytokines like transforming growth factor beta 1 (TGF-β1), platelet-derived growth factor (PDGF), and reactive oxygen species (ROS). Myofibroblasts overexpress type I collagen and extracellular matrix proteins, leading to plaque formation. In the chronic presentation, inflammation is reduced, but the fibrotic plaque is preserved, and partial calcification occurs in most cases. This causes structural deformity of the penile tissue and inelasticity that impedes normal growth during an erection. Intense calcification and fibrosis impair normal hemodynamics and penile elasticity of the penis, which usually causes venous leakage and erectile failure.
=== Antibiotics created from 6-APA === There are three major groups of other semi-synthetic antibiotics related to the penicillins. They are synthesised by adding various side-chains to the precursor 6-APA, which is isolated from penicillin G. These are the antistaphylococcal antibiotics, broad-spectrum antibiotics and antipseudomonal antibiotics.
Assam Asimov (アサム・アシモフ, Asamu Ashimofu) and Mugi Grafton (ムギ・グラフトン, Mugi Gurafuton): Two of Reidlich's underlings who work undercover in S.P.D.'s Earth unit as Neo Deka Red (ネオデカレッド, Neo Deka Reddo) and Neo Deka Yellow (ネオデカイエロー, Neo Deka Ierō), respectively, and appear exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After. After failing to kidnap Carrie and being defeated by Deka Blue, Green, Yellow, and Pink, Reidlich forcibly converts Asimov and Grafton into energy to power his Neo Hyper Muscle Gear. Assam Asimov and Mugi Grafton are portrayed by Rakuto Tochihara (栩原 楽人, Tochihara Rakuto) and Mizuho Hata (秦 瑞穂, Hata Mizuho), respectively. Clementian Carrie (クレメント星人キャリー, Kuremento Seijin Kyarī): A girl from Planet Clement, whose inhabitants can enter the bodies of others for concealment, who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After. Two years prior, she and her father accidentally stumbled onto Kruger discovering Kight Reidlich's corruption. After Reidlich killed Carrie's father, Kruger told Carrie to find his team. She went into hiding before eventually coming to Earth in the present. Upon finding the Dekarangers, they escort her to Planet Gowashichoru before confronting Reidlich. Carrie is portrayed by Rino Kobayashi (小林 里乃, Kobayashi Rino). Rui Edogawa (江戸川 塁, Edogawa Rui): A rookie S.P.D.
As of 2022, TikTok is the 10th most popular app in Russia. After a new set of Russian war censorship laws was installed in March 2022, the company announced a series of restrictions on Russian and non-Russian posts and livestreams. Tracking Exposed, a user data rights group, learned of what was likely a technical glitch that became exploited by pro-Russia posters. It stated that although this and other loopholes were patched by TikTok before the end of March, the initial failure to correctly implement the restrictions, in addition to the effects from Kremlin's "fake news" laws, contributed to the formation of a "splInternet ... dominated by pro-war content" in Russia. TikTok said that it had removed 204 accounts for swaying public opinion about the war while obscuring their origins and that its fact checkers had removed 41,191 videos for violating its misinformation policies. In December 2023, BBC News reported that it had discovered nearly 800 fake TikTok accounts promoting Russian propaganda and disinformation. TikTok's own investigation found more than 12,000 fake accounts, including ones using additional languages such as English and Italian. In September 2024, TikTok removed the accounts of Russian state media outlets RT and Sputnik.
Sources: en.wikipedia.org
A 2018 systematic review of progesterone and breast cancer concluded that short-term use (<5 years) of an estrogen plus progesterone is not associated with a significant increase in risk of breast cancer but that long-term use (>5 years) is associated with greater risk. The conclusions for progesterone were the same in a 2019 meta-analysis of the worldwide epidemiological evidence by the Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC). Most data on breast density changes and breast cancer risk are with oral progesterone. Data on breast safety with vaginal progesterone are scarce. The Early versus Late Intervention Trial with Estradiol (ELITE) was a randomized controlled trial of about 650 postmenopausal women who used estradiol and 45 mg/day cyclic vaginal progesterone. Incidence of breast cancer was reported as an adverse effect. The absolute incidences were 10 cases in the estradiol plus vaginal progesterone group and 8 cases in the control group. However, the study was not adequately powered for quantifying breast cancer risk.
The Israeli Sayeret Matkal and Shaldag units have also been modelled after the SAS, sharing its motto. Ireland's Army Ranger Wing (ARW) also trains with the SAS. The Philippine National Police's Special Action Force was formed along the lines of the SAS. The former Royal Afghan Army's 666th Commando Brigade was formed by Colonel Rahmatullah Safi in the 1970s after he received his training with the SAS before it was disbanded through purges after the coups in 1973 and 1978.
All the alkali metals have odd atomic numbers; hence, their isotopes must be either odd–odd (both proton and neutron number are odd) or odd–even (proton number is odd, but neutron number is even). Odd–odd nuclei have even mass numbers, whereas odd–even nuclei have odd mass numbers. Odd–odd primordial nuclides are rare because most odd–odd nuclei are highly unstable with respect to beta decay, because the decay products are even–even, and are therefore more strongly bound, due to nuclear pairing effects. Due to the great rarity of odd–odd nuclei, almost all the primordial isotopes of the alkali metals are odd–even (the exceptions being the light stable isotope lithium-6 and the long-lived radioisotope potassium-40). For a given odd mass number, there can be only a single beta-stable nuclide, since there is not a difference in binding energy between even–odd and odd–even comparable to that between even–even and odd–odd, leaving other nuclides of the same mass number (isobars) free to beta decay toward the lowest-mass nuclide. An effect of the instability of an odd number of either type of nucleons is that odd-numbered elements, such as the alkali metals, tend to have fewer stable isotopes than even-numbered elements. Of the 26 monoisotopic elements that have only a single stable isotope, all but one have an odd atomic number and all but one also have an even number of neutrons. Beryllium is the single exception to both rules, due to its low atomic number.
"Absinthe's second coming" Archived 2008-12-03 at the Wayback Machine – An April 2001 article in Cigar Aficionado about the first absinthe commercially produced in France since the 1915 ban. "Swiss face sobering future after legalizing absinthe" Archived 2016-12-02 at the Wayback Machine – A March 2005 Reuters article about the legalising of absinthe in Switzerland. "The Mystery of the Green Menace" – A November 2005 Wired magazine article about a New Orleans man who has researched the chemical content of absinthe and now distills it in France "The Return of the Green Faerie" – A wine and spirit journal article about the history, ritual, and artistic cult of absinthe The Wormwood Society Archived 2006-04-24 at the Wayback Machine – An independent organisation supporting changes to the US laws and regulations concerning absinthe. Provides articles, a forum and legal information. "What Is Absinthe" – Article discussing absinthe and its effect over mind and body. Absinthe in the online Culinary Heritage of Switzerland database.
Lymphocyte T-cell immunomodulator (LTCI) is an immune regulating polypeptide, which is a potent regulator of CD-4 lymphocyte production and function. It increases lymphocyte numbers and interleukin-2 (IL-2) production in animals. It is extracted from bovine thymus.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.